Jinhang Che, Yi Wang, Lihong Luo, Yunxiang Tang, Jie Huai, Tao Zeng, Zengzhang Liu
{"title":"1990-2021年204个国家和地区高血压心脏病负担及其归因危险因素：来自2021年全球疾病负担研究的结果","authors":"Jinhang Che, Yi Wang, Lihong Luo, Yunxiang Tang, Jie Huai, Tao Zeng, Zengzhang Liu","doi":"10.1111/eci.70104","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypertensive heart disease (HHD) remains a significant global health issue.</p><p><strong>Methods: </strong>This study analysed the global, regional, and national burden of HHD from 1990 to 2021.</p><p><strong>Results: </strong>In 2021, the global prevalence, deaths, and disability-adjusted life years (DALYs) associated with HHD were 12.5 million, 1.3 million and 25.5 million, respectively, exhibiting age-standardized percentage changes of 18.2%, -22.0% and -25.8% compared to 1990. Jordan (341.9), Bulgaria (103.4) and Bulgaria (1739.3) had the highest age-standardized prevalence, death and DALY rates, respectively, while Belarus recorded the lowest rates. DALYs reached their zenith in the 70-74 age range, but age-standardized DALY rates were rising in the oldest age group (≥95). A negative correlation was observed between the sociodemographic index and DALY rates. The key risk factors identified were high systolic blood pressure (100%), high BMI (49.3%) and insufficient fruit intake (37.8%).</p><p><strong>Conclusion: </strong>Although case numbers have increased, age-standardised death and DALY rates have declined since 1990. Targeted prevention strategies should prioritise blood pressure control, weight management and dietary measures to mitigate the burden of HHD.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70104"},"PeriodicalIF":3.6000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Burden of hypertensive heart disease and its attributable risk factors in 204 countries and territories, 1990-2021: Results from the global burden of disease study 2021.\",\"authors\":\"Jinhang Che, Yi Wang, Lihong Luo, Yunxiang Tang, Jie Huai, Tao Zeng, Zengzhang Liu\",\"doi\":\"10.1111/eci.70104\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hypertensive heart disease (HHD) remains a significant global health issue.</p><p><strong>Methods: </strong>This study analysed the global, regional, and national burden of HHD from 1990 to 2021.</p><p><strong>Results: </strong>In 2021, the global prevalence, deaths, and disability-adjusted life years (DALYs) associated with HHD were 12.5 million, 1.3 million and 25.5 million, respectively, exhibiting age-standardized percentage changes of 18.2%, -22.0% and -25.8% compared to 1990. Jordan (341.9), Bulgaria (103.4) and Bulgaria (1739.3) had the highest age-standardized prevalence, death and DALY rates, respectively, while Belarus recorded the lowest rates. DALYs reached their zenith in the 70-74 age range, but age-standardized DALY rates were rising in the oldest age group (≥95). A negative correlation was observed between the sociodemographic index and DALY rates. The key risk factors identified were high systolic blood pressure (100%), high BMI (49.3%) and insufficient fruit intake (37.8%).</p><p><strong>Conclusion: </strong>Although case numbers have increased, age-standardised death and DALY rates have declined since 1990. Targeted prevention strategies should prioritise blood pressure control, weight management and dietary measures to mitigate the burden of HHD.</p>\",\"PeriodicalId\":12013,\"journal\":{\"name\":\"European Journal of Clinical Investigation\",\"volume\":\" \",\"pages\":\"e70104\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/eci.70104\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.70104","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Burden of hypertensive heart disease and its attributable risk factors in 204 countries and territories, 1990-2021: Results from the global burden of disease study 2021.
Background: Hypertensive heart disease (HHD) remains a significant global health issue.
Methods: This study analysed the global, regional, and national burden of HHD from 1990 to 2021.
Results: In 2021, the global prevalence, deaths, and disability-adjusted life years (DALYs) associated with HHD were 12.5 million, 1.3 million and 25.5 million, respectively, exhibiting age-standardized percentage changes of 18.2%, -22.0% and -25.8% compared to 1990. Jordan (341.9), Bulgaria (103.4) and Bulgaria (1739.3) had the highest age-standardized prevalence, death and DALY rates, respectively, while Belarus recorded the lowest rates. DALYs reached their zenith in the 70-74 age range, but age-standardized DALY rates were rising in the oldest age group (≥95). A negative correlation was observed between the sociodemographic index and DALY rates. The key risk factors identified were high systolic blood pressure (100%), high BMI (49.3%) and insufficient fruit intake (37.8%).
Conclusion: Although case numbers have increased, age-standardised death and DALY rates have declined since 1990. Targeted prevention strategies should prioritise blood pressure control, weight management and dietary measures to mitigate the burden of HHD.
期刊介绍：
EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
